Partnering Opportunities

Rexahn seeks to establish global and regional strategic alliances and partnerships that complement our expertise in oncology product development.

We continually review opportunities to in-license and advance compounds in oncology that have value-creating potential and will strengthen our clinical development pipeline.

Interested in Collaborating?

For more information about our products or to send us information about your products and technologies, please email us

Current Collaborators


BioSense is an emerging biotech company established to address the business needs of the global biopharmaceutical market with a focus on China, Europe, and the U.S. The company is based in New Jersey (US) and Suzhou (China). The organization’s mission is to bridge the gap between undercapitalized biopharmaceutical projects, resources and markets to add value to its stakeholders and address significant unmet medical needs and bring affordable treatment options to patients. BioSense’s expert team of international biopharma executives and seasoned investors has extensive experience in developing, registering and commercializing some of the most successful products in key markets, including, US, Europe and China, plus the business management and cross-cultural knowledge.

Learn More

Merck & Co.

Rexahn has entered into a collaboration agreement with Merck to evaluate RX-5902 in combination with Keytruda® in triple negative breast cancer TNBC.

Learn More

Zhejiang Haichang Biotechnology Co., Ltd.

Zhejiang Haichang Biotechnology Co., Ltd. is a privately-owned specialized biotechnology company headquartered in Hangzhou, China, focused on the development and manufacture of complex intravenous pharmaceutical products including liposome and microsphere products, primarily for cancer treatment.

Learn More